Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Zander

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Bone Marrow Transplantation|May 30, 2003
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)Nicolaus Kröger, Hermann Einsele, Daniel Wolff, et al.
Haematologica|March 13, 2009
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantationNicolaus Kröger, Ronald Brand, Anja van Biezen, et al.
Experimental Hematology|June 3, 2009
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myelomaNicolaus Kröger, Anita Badbaran, Michael Lioznov, et al.
Blood|July 7, 2005
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMTCharles Crawley, Richard Szydlo, Marc Lalancette, et al.
Human Gene Therapy|November 25, 2010
Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010)Carol Stocking, Manuel Grez, Boris Fehse, et al.
Blood|February 26, 2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMTCharles Crawley, Marc Lalancette, Richard Szydlo, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Bone Marrow Transplantation|May 30, 2003
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)Nicolaus Kröger, Hermann Einsele, Daniel Wolff, et al.
Haematologica|March 13, 2009
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantationNicolaus Kröger, Ronald Brand, Anja van Biezen, et al.
Experimental Hematology|June 3, 2009
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myelomaNicolaus Kröger, Anita Badbaran, Michael Lioznov, et al.
Blood|July 7, 2005
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMTCharles Crawley, Richard Szydlo, Marc Lalancette, et al.
Human Gene Therapy|November 25, 2010
Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010)Carol Stocking, Manuel Grez, Boris Fehse, et al.
Blood|February 26, 2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMTCharles Crawley, Marc Lalancette, Richard Szydlo, et al.
Pageof 4